Showing results 1 to 20 of 87
next >
| Issue Date | Title | Author(s) | Type | Мp-cat. |
| 2022 | 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer | Verschraegen, Claire; Andric, Zoran G   ; ...; (broj, koautora 20) | Conference Paper | |
| 2024 | 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer | Verschraegen, C; Andric, Zoran G ; Moiseenko, FV; Makharadze, T; Oleksiienko, A; Ruiz, EP Yanez; Kim, SH; Ahn, K; Park, TH; Ju, HA;
Baek, EH; Kwon, S; Lee, SJ; Chang, I; Kim, SH; Kim, HA; Lee, E; Ohe, Y;
| Conference Paper | |
| 2006 | 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC) | Andric, Zoran G ; Murtezani, Zafir; Kovcin, Vladimir N; Gutovic, Jasmina; Kostic, Sanja V | Conference Paper | |
| 2021 | 565Tip A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer | Abramson, V; ...; Andric, Zoran G ; Milovic-Kovacevic, Marijana M ; Trifunovic, Jasna D; ...; (broj, koautora 16) | Conference Paper | |
| 2021 | A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction. | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zoran; ...; (broj, koautora 17) | Conference Paper | |
| 2021 | A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression | Andric, Zoran G ; Ceric, Timur; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Ulanska, M; Caldwell, C; Ferrari, D; Annis, A;
Vukovic, V; Zaric, Bojan ; | Conference Paper | |
| 2013 | A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). | Ramalingam, Suresh S; ...; Andric, Zoran G ; ...; Zaric, Bojan ; ...; Vukovic, Vojislav M; ...; (broj, koautora 20) | Conference Paper | |
| 2013 | Analysis of clinicopathological characteristics of 982 lung cancer patients and subsequent treatment Epidemiology study | Jovanovic, Dragana D; Secen, Nevena M; Murtezani, Zafir; Rancic, Milan H ; Kacar-Kukric, Vesna D; Velinovic, Marta; Tepavac, Ana; Budisin, Evica S; Andric, Zoran G ; Vukobradovic-Djoric, Nevena | Conference Paper | |
| 2021 | Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C | Dziadziuszko, R; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | |
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 22) | Article | |
| 2022 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial | Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26) | Article | |
| 2023 | Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC | Andric, Zoran G ; ...; Stojanovic, Goran; Petrovic, Marina D ; ...; (broj, koautora 21) | Article | |
| 2024 | Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial | Reck, Martin; ...; Andric, Zoran G ; ...; (broj, koautora 18) | Article | |
| 2022 | Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100 | Reck, M; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Conference Paper | |
| 2021 | Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis. | Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas;
Garcia, Fernanda;
| Conference Paper | |
| 2020 | Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study. | Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, Cristina | Conference Paper | |
| 2022 | Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial | Verschraegen, Claire; Andric, Zoran G ; Moiseenko, Fedor; Makharadze, Tamta; Shevnya, Sergii; Oleksiienko, Alona; Ruiz, Eduardo Yanez; Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong;
Park, Sijin; Ju, Hana; Ohe, Yuichiro;
| Article | |
| 2012 | Characteristics of 982 Lung Cancer Patients in Serbia According to the Who/Iaslc Classification of Lung Cancers and Subsequent Treatment Avatar Epidemiology Study | Jovanovic, Dusan; Secen, Nevena M; Murtezani, Zafir; Rancic, Milan H ; Kacar-Kukric, Vesna D; Velinovic, Milos M; Tepavac, Aleksandar; Budisin, Evica S; Andric, Zoran G ; Vukobradovic-Djoric, Nevena | Conference Paper | |
| 2019 | Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 | Siefker-Radtke, Arlene O; Lugowska, Iwona; Tupikowski, Krzysztof; Andric, Zoran G ; Rezazadeh-Kalebasty, A; Curigliano, Giuseppe; Vaena, Daniel A; Vogl, FD; Currie, Graeme; Abella, S;
Kelly, William Kevin;
| Conference Paper | |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Conference Paper | |